Biotechnology

WeTrade Group Announces the Launch of Global Payment System WTPay and Development Plan of Health Business

BEIJING, Oct. 18, 2022 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG), a global diversified "software as a service" ("SaaS") technology service provider which is committed to providing technical support and digital transformation tools for enterprises across differ...

2022-10-18 17:02 3002

NEC Selected as Technology Partner in the Implementation of Biometric Solutions for NIISe

KUALA LUMPUR, Malaysia, Oct. 18, 2022 /PRNewswire/ -- Leading IT and Network Technologies company, NEC Corporation of Malaysia Sdn Bhd (NEC Malaysia) has been awarded the sub-contract for the implementation of its class leading Automated Biometric Identification System (NEC ABIS) and Border Contr...

2022-10-18 17:01 1863

ImmVira announced to launch the construction of Global R&D and Commercialization Base

SHENZHEN, China, Oct. 18, 2022 /PRNewswire/ -- On October 18, 2022, ImmVira launched the construction of its Global R&D and Commercialization Base in Suzhou Wuzhong Biomedical Industrial Park (Lifebay),China. The day before, ImmVira's "Shanghai Business and Clinical Center" officially opened on t...

2022-10-18 16:22 1177

EditForce Realizes RNA-editing Technology of "U-to-C"

FUKUOKA, Japan, Oct. 18, 2022 /PRNewswire/ -- EditForce, Inc. (hereinafter "EditForce"), headquartered inFukuoka, Japan, has realized the world's first RNA-editing technology that enables RNA-editing bases to be changed from "U" to "C," and demonstrated that this technology works even in human ce...

2022-10-18 14:00 1250

iNtRON developed advanced bacteriophage engineering platform technology based on modified random mutagenesis

* The transposon technology development following the customized CRISPR/Cas system for bacteriophage * 2nd Generation technology of Robot Bacteriophage BOSTON and SEOUL, South Korea, Oct. 17, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com

2022-10-18 11:56 1488

GenScript ProBio Signs MOU to Form Strategic Partnership with GeneCraft To Development and Production of New AAV gene therapies

SEOUL, South Korea, Oct. 18, 2022 /PRNewswire/ -- On the Oct 17, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and GeneCraft  (Suk Chul Bae, CEO), a global research team led by Professor Suk Chul Bae of lung cancer mechanism research, announced that they had entered into a strat...

2022-10-18 08:00 1982

InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022

NANJING, China, Oct. 17, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology companydedicated to developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, is pleased to announce that the clinical data from an open-label, phase Ib trial evaluating t...

2022-10-18 08:00 1149

TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM

* OPALESCENCE Phase II feasibility study of TLX250-CDx in patients with triple-negative breast cancer – early results suggest potential to detect carbonic anhydrase IX (CAIX) expression, theranostic potential in this difficult to treat disease. * PERTINENCE Early Phase I feasibility study of ...

2022-10-18 06:43 1531

GenScript ProBio Enters Strategic Collaboration with Hibiocy Co. Ltd, the affiliate of Rojukiss International Public Company Limited (KISS) - the leading Thai-based Beauty & Health company, for the development and manufacturing of COVITRAP™ and future new products.

SINGAPORE, Oct. 17, 2022 /PRNewswire/ -- GenScript ProBio (a global one-stop CDMO from GenScript Group) today announced a strategic collaboration with Hibiocy Co. Ltd., a private corporation based inBangkok, Thailand, to accelerate a respiratory-care medical device, COVITRAP™ which contains human...

2022-10-17 23:56 4810

Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia

Clinical trial assessing allogeneic, HLA-matched, donor-derived allogeneic CAR-T therapy SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Oct. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicat...

2022-10-17 20:05 1208

PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022

DAEJEON, South Korea, Oct. 17, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company's first immuno-oncology dru...

2022-10-17 20:00 1190

Innovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalMedicine

ROCKVILLE, Md. and SUZHOU, China, Oct. 17, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major d...

2022-10-17 08:00 3430

Kira Pharmaceuticals Announces IND Approval from Chinese NMPA for Phase 2 Evaluation of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)

CAMBRIDGE, Mass. and SUZHOU, China, Oct. 17, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, announced today that the Chinese National Medical Products Administration (NMPA) has cleared t...

2022-10-17 07:31 1892

Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging

MELBOURNE, Australia, Oct. 17, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved an investigational new drug (IND) application to commence...

2022-10-17 07:25 1601

Angel Yeast Announces to Promote Food Security and Sustainable Agriculture on the World Food Day

YICHANG, China, Oct. 16, 2022 /PRNewswire/ -- Angel Yeast , (SH600298), the world's leading yeast manufacturer, has announced it aims to play a larger role in increasing people's access to nutritious food, and making food systems more inclusive and sustainable, as par...

2022-10-16 21:00 3446

China Matters' Feature: How is Dongguan changing manufacturing with 3D printing?

BEIJING, Oct. 14, 2022 /PRNewswire/ -- Dongguan has long been known as the "factory of the world." The city has produced one third of the world's accessories and daily goods, and one out of six phones in the world is made from here. But over the recent years, the city has been shifting to a mode...

2022-10-14 21:22 3285

Tianfu International Biocity: Build Global Bioindustry-city

CHENGDU, China, Oct. 14, 2022 /PRNewswire/ -- On Oct.10, Chengdu Tianfu Global International Biocity saw the signing of ten project agreements totalling nearly 9B CNY in value and covering modern biopharmaceuticals, innovative chemical drugs, sophisticated medical apparatuses and other important f...

2022-10-14 20:48 1367

WuXi Biologics Receives "Best CDMO Award of the Year"

SHANGHAI, Oct. 13, 2022  /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received the "Best CDMO Award of the Year" at the Asia-Pacific Biologics CMO Excellence Awards (APBCEA) 202...

2022-10-14 09:00 1728

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy

Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Oct. 13, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying t...

2022-10-13 22:25 1276

Neurophth Therapeutics Conducts Special Interview with Dr. Satoshi Kashii on World Sight Day

WUHAN, China and SAN DIEGO, Calif., Oct. 13, 2022 /PRNewswire/ -- October 13th is World Sight Day.Today, Neurophth Therapeutics, Inc. has a special interview with Dr.Satoshi Kashii, Professor of Visual Sciences and Ophthalmology, Aichi Shukutoku University, President of Asian Neuro-Ophthalmology ...

2022-10-13 20:30 2131
1 ... 147148149150151152153 ... 307